|By Marketwired .||
|August 14, 2014 09:28 PM EDT||
REYKJAVIK, ICELAND and ISAFJORDUR, ICELAND -- (Marketwired) -- 08/14/14 -- Kerecis Limited, the emerging leader in tissue-regeneration materials, will participate in the Military Health System Research Symposium (MHSRS) August 18 to 21. Kerecis will exhibit its wound treatment technology in booth 48 of the Marriott Harbor Beach Resort, Fort Lauderdale, Florida.
The Kerecis Omega3 fish-skin regenerative surgical material has been developed for multiple indications, including wound treatment and tissue reconstruction.
The first Kerecis product, Kerecis Omega3 Wound, is indicated for the management of chronic wounds including diabetic, vascular and other hard-to-heal wounds. When inserted into or onto damaged human tissue, the Kerecis Omega3 products recruit the body's own cells, are incorporated into the wound, and ultimately are converted into functional, living tissue.
The MHSRS is the Department of Defense's (DoD) premier scientific meeting. This joint symposium provides a collaborative environment for military medical care providers with deployment experience, DoD scientists, academia and industry to exchange information on research and health care advancements within the areas of combat casualty care, military operational medicine, clinical and rehabilitative medicine, and military infectious disease research programs.
G. Fertram Sigurjonsson, President and CEO, Kerecis Limited
"The military have unique medical needs, including treating debilitating or otherwise hard-to-heal wounds. We believe that the Kerecis Omega3 technology can optimize care for the wounded members of the U.S. armed forces."
Kerecis develops tissue-regeneration biologic matrixes consisting of patented Omega3-containing fish skin. Production takes place in Kerecis' manufacturing facilities in Iceland. Biologic matrixes are materials made from human or animal tissue where the original material is intact, but all cells and antigenic materials have been removed. The Kerecis fish-skin material accelerates wound healing and enables tissue reconstruction.
This FDA-approved material offers advantages over existing human- and porcine-derived products, including improved manufacturing economics and a lower risk of disease transfer. Since it is derived from fish, the material is both kosher and halal compatible, eliminating cultural and religious constraints to usage, with equivalent or better clinical performance than alternative approaches.
The Kerecis technology has received U.S. patents, and has patents pending in multiple countries around the world. The materials are available in Iceland, Denmark, the UK, Turkey and several Middle East and Asian markets. Distributor inquiries are welcome. For more information, visit www.kerecis.com.
For further information, contact:
G. Fertram Sigurjonsson
President and CEO
Phone (Iceland) +354-8494960
E-mail: Email Contact